AnalgesiaNCT07246694
Enhanced Recovery After Uvulopalatoplasty
A study testing Glossopharyngeal nerve block and Standard multimodal analgesia in people with Analgesia and Recovery, Psychological, run by Zagazig University at 1 site in Egypt.
Trial summary
Obstructive sleep apnea is a prevalent condition often treated surgically with palatoplasty, which improves airway patency and reduces apneic events. However, postoperative pain and airway discomfort following palatoplasty can be significant, leading to delayed oral intake, increased opioid consumption, and prolonged… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Analgesia, Recovery, Psychological
- What is being tested?
- Glossopharyngeal nerve block and Standard multimodal analgesia
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Dec 2025to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Confirmed diagnosis of moderate to severe obstructive sleep apnea.
- Patients scheduled for elective palatoplasty under general anesthesia.
- American Society of Anesthesiologists Physical Status class I and II.
Who cannot join
- Patients with chronic opioid use.
- Advanced hepatic, renal, cardiovascular, and neurologic diseases.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Combined Glossopharyngeal Nerve Block With Topical Anesthesia for Enhanced Recovery in Obstructive Sleep Apnea Patients Undergoing Uvulopalatoplasty
Obstructive sleep apnea is a prevalent condition often treated surgically with palatoplasty, which improves airway patency and reduces apneic events. However, postoperative pain and airway discomfort following palatoplasty can be significant, leading to delayed oral intake, increased opioid consumption, and prolonged recovery. Combining an ultrasound-guided glossopharyngeal nerve block with topical airway anesthesia may provide synergistic analgesia and support a safer recovery profile.
Read the detailed description
Obstructive sleep apnea is a prevalent condition often treated surgically with palatoplasty, which improves airway patency and reduces apneic events. However, postoperative pain and airway discomfort following palatoplasty can be significant, leading to delayed oral intake, increased opioid consumption, and prolonged recovery. Enhanced Recovery After Surgery protocols aim to accelerate functional recovery and reduce perioperative morbidity. Combining an ultrasound-guided glossopharyngeal nerve block with topical airway anesthesia may provide effective analgesia and support a smoother recovery profile.
- Conditions
- Analgesia, Recovery, Psychological
- Being tested
- Glossopharyngeal nerve block, Standard multimodal analgesia
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Glossopharyngeal nerve blockProcedure or surgery
Glossopharyngeal nerve block using ultrasound guidance after induction of general anesthesia plus topical anesthesia before surgical incision.
Standard multimodal analgesiaOther
The patient will receive intravenous fentanyl and non opioids analgesics (acetaminophen and non-steroidal anti-inflammatory drugs) with general anesthesia.
| Study group | Role | What they receive |
|---|---|---|
| Group I | Active comparator | The patient will receive the ultrasound-guided glossopharyngeal nerve block combined with topical airway anesthesia. Receives: Procedure: Glossopharyngeal nerve block |
| Group c | Active comparator | The patient will receive the standard multimodal analgesia. Receives: Other: Standard multimodal analgesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
The recovery time
The time from from inhalational anesthetic discontinuation to the first response to verbal command.
Measured: 1 hour
Secondary outcomes (5)
Additional intraoperative analgesia
Additional doses of intraoperative fentanyl.
Measured: 4 hours
Postoperative pain assessment
Postoperative pain assessment by the 10 points Visual Analogue Scale at at rest and during swallowing with 0 indicates no pain and 10 indicates the worst pain.
Measured: The first 24 hours postoperative.
Total rescue analgesia
Total rescue analgesic dose needed during the first postoperative 24 hours.
Measured: The first 24 hours postoperative.
Incidence of complications
Incidence of any complications related to nerve block or local anesthesia such as hematoma formation or local anesthetic systemic toxicity.
Measured: 4 hours
Quality of recovery
Quality of recovery assessed by the Quality of recovery score-15 at the end of the first 24 hours postoperative. The Quality of recovery score ranges from 0 to150, with higher scores indicate better recovery.
Measured: The first 24 hours postoperative.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start1 Dec 2025
- Primary completionDec 2026 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnalgesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Fatma Mahmoud Ahmed, MD, Principal investigator, Department of Anesthesia, Intensive Care & Pain Management, Zagazig UniversityAlshaimaa Abdelfattah Kamel, MD, Study director, Department of Anesthesia, Intensive Care & Pain Management, Zagazig UniversityOsama Yehia Khalifa, MD, Study director, Department of Anesthesia, Intensive Care & Pain Management, Zagazig University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07246694
- Sponsor's protocol ID
- Uvulopalatoplasty Analgesia
- Status last verified
- Nov 2025
- First submitted
- 17 Nov 2025
- Last updated
- 6 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Glossopharyngeal Nerve Block With Topical Anesthesia for Enhanced Recovery in Obstructive Sleep Apnea Patients Undergoing Uvulopalatoplasty
- ClinicalTrials.gov ID
- NCT07246694
- Acronym / sponsor ID
- Uvulopalatoplasty Analgesia
- Conditions
- Analgesia, Recovery, Psychological
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive sleep apnea is a prevalent condition often treated surgically with palatoplasty, which improves airway patency and reduces apneic events. However, postoperative pain and airway discomfort following palatoplasty can be significant, leading to delayed oral intake, increased opioid consumption, and prolonged recovery. Combining an ultrasound-guided glossopharyngeal nerve block with topical airway anesthesia may provide synergistic analgesia and support a safer recovery profile.
Detailed description
Obstructive sleep apnea is a prevalent condition often treated surgically with palatoplasty, which improves airway patency and reduces apneic events. However, postoperative pain and airway discomfort following palatoplasty can be significant, leading to delayed oral intake, increased opioid consumption, and prolonged recovery. Enhanced Recovery After Surgery protocols aim to accelerate functional recovery and reduce perioperative morbidity. Combining an ultrasound-guided glossopharyngeal nerve block with topical airway anesthesia may provide effective analgesia and support a smoother recovery profile.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I | Active comparator | Procedure: Glossopharyngeal nerve blockThe patient will receive the ultrasound-guided glossopharyngeal nerve block combined with topical airway anesthesia. |
| Group c | Active comparator | Other: Standard multimodal analgesiaThe patient will receive the standard multimodal analgesia. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Confirmed diagnosis of moderate to severe obstructive sleep apnea.
- Patients scheduled for elective palatoplasty under general anesthesia.
- American Society of Anesthesiologists Physical Status class I and II.
Key exclusion criteria (2 listed)
- Patients with chronic opioid use.
- Advanced hepatic, renal, cardiovascular, and neurologic diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Glossopharyngeal nerve blockGlossopharyngeal nerve block using ultrasound guidance after induction of general anesthesia plus topical anesthesia before surgical incision. | Procedure or surgery | Group I |
| Standard multimodal analgesiaThe patient will receive intravenous fentanyl and non opioids analgesics (acetaminophen and non-steroidal anti-inflammatory drugs) with general anesthesia. | Other | Group c |
Primary outcome
The recovery time
Time frame: 1 hour
The time from from inhalational anesthetic discontinuation to the first response to verbal command.
5 secondary outcomes
Additional intraoperative analgesia
Time frame: 4 hours
Postoperative pain assessment
Time frame: The first 24 hours postoperative.
Total rescue analgesia
Time frame: The first 24 hours postoperative.
Incidence of complications
Time frame: 4 hours
Quality of recovery
Time frame: The first 24 hours postoperative.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
Related trials for Analgesia
Recruiting
NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia
Intraoperative Analgesia
RecruitingPhase 4
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Laparoscopic Surgery, Visceral Pain, Postoperative
RecruitingPhase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
Mechanical Ventilation, Pediatric Acute Respiratory Failure
RecruitingPhase 4
Adding Dexmedetomidine or Clonidine to Spinal Anesthesia for Cesarean Delivery
Cesarean Delivery, Cesarean Delivery; Neuraxial Opioids
Not yet recruitingPhase 4
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fatma Mahmoud Ahmed, MD principal investigator
Department of Anesthesia, Intensive Care & Pain Management, Zagazig University
Alshaimaa Abdelfattah Kamel, MD study director
Department of Anesthesia, Intensive Care & Pain Management, Zagazig University
Osama Yehia Khalifa, MD study director
Department of Anesthesia, Intensive Care & Pain Management, Zagazig University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glossopharyngeal nerve block and Standard multimodal analgesia in people with Analgesia and Recovery, Psychological, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The recovery time (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.